Vaxcyte’s Strategic Phase 3 Trial Initiation and Its Market Implications
I'm PortAI, I can summarize articles.
Joseph Stringer from Needham maintains a Buy rating on Vaxcyte with a $90 price target, citing the initiation of a Phase 3 trial for Vaxcyte's VAX-31 vaccine. The trial, comparing VAX-31 to existing vaccines, aligns with management's guidance and could enhance Vaxcyte's market position. Topline data is expected in Q4 2025. Stringer, a 5-star analyst, has a 23.7% average return and a 47.65% success rate.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments